262 related articles for article (PubMed ID: 26567283)
1. Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.
Petraitiene R; Petraitis V; Hope WW; Walsh TJ
Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S643-51. PubMed ID: 26567283
[TBL] [Abstract][Full Text] [Related]
2. Single or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna!
Gumbo T
Clin Infect Dis; 2015 Dec; 61 Suppl 6():S635-42. PubMed ID: 26567282
[TBL] [Abstract][Full Text] [Related]
3. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitis V; Petraitiene R; Groll AH; Roussillon K; Hemmings M; Lyman CA; Sein T; Bacher J; Bekersky I; Walsh TJ
Antimicrob Agents Chemother; 2002 Jun; 46(6):1857-69. PubMed ID: 12019101
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
[TBL] [Abstract][Full Text] [Related]
5. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.
Andes DR; Diekema DJ; Pfaller MA; Marchillo K; Bohrmueller J
Antimicrob Agents Chemother; 2008 Oct; 52(10):3497-503. PubMed ID: 18625768
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits.
Petraitiene R; Petraitis V; Kelaher AM; Sarafandi AA; Mickiene D; Groll AH; Sein T; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2005 May; 49(5):2084-92. PubMed ID: 15855534
[TBL] [Abstract][Full Text] [Related]
7. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
Mehta PA; Vinks AA; Filipovich A; Bleesing J; Jodele S; Jordan MB; Marsh R; Tarin R; Edwards S; Fearing D; Lawrence J; Davies SM
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1458-62. PubMed ID: 20546908
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.
Howard SJ; Livermore J; Sharp A; Goodwin J; Gregson L; Alastruey-Izquierdo A; Perlin DS; Warn PA; Hope WW
Antimicrob Agents Chemother; 2011 Oct; 55(10):4880-7. PubMed ID: 21807969
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid and plasma (1-->3)-beta-D-glucan as surrogate markers for detection and monitoring of therapeutic response in experimental hematogenous Candida meningoencephalitis.
Petraitiene R; Petraitis V; Hope WW; Mickiene D; Kelaher AM; Murray HA; Mya-San C; Hughes JE; Cotton MP; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2008 Nov; 52(11):4121-9. PubMed ID: 18779361
[TBL] [Abstract][Full Text] [Related]
10. High-Dose Micafungin for Preterm Neonates and Infants with Invasive and Central Nervous System Candidiasis.
Auriti C; Falcone M; Ronchetti MP; Goffredo BM; Cairoli S; Crisafulli R; Piersigilli F; Corsetti T; Dotta A; Pai MP
Antimicrob Agents Chemother; 2016 Dec; 60(12):7333-7339. PubMed ID: 27697761
[TBL] [Abstract][Full Text] [Related]
11. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.
Gumbo T; Drusano GL; Liu W; Kulawy RW; Fregeau C; Hsu V; Louie A
Antimicrob Agents Chemother; 2007 Mar; 51(3):968-74. PubMed ID: 17194830
[TBL] [Abstract][Full Text] [Related]
12. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits.
Petraitiene R; Petraitis V; Groll AH; Candelario M; Sein T; Bell A; Lyman CA; McMillian CL; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 1999 Sep; 43(9):2148-55. PubMed ID: 10471556
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of micafungin in neonates and young infants.
Hope WW; Smith PB; Arrieta A; Buell DN; Roy M; Kaibara A; Walsh TJ; Cohen-Wolkowiez M; Benjamin DK
Antimicrob Agents Chemother; 2010 Jun; 54(6):2633-7. PubMed ID: 20308367
[TBL] [Abstract][Full Text] [Related]
14. Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin.
Slater JL; Howard SJ; Sharp A; Goodwin J; Gregson LM; Alastruey-Izquierdo A; Arendrup MC; Warn PA; Perlin DS; Hope WW
Antimicrob Agents Chemother; 2011 Jul; 55(7):3075-83. PubMed ID: 21502627
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation.
Autmizguine J; Hornik CP; Benjamin DK; Brouwer KL; Hupp SR; Cohen-Wolkowiez M; Watt KM
Pediatr Infect Dis J; 2016 Nov; 35(11):1204-1210. PubMed ID: 27314826
[TBL] [Abstract][Full Text] [Related]
16. Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis.
Benjamin DK; Deville JG; Azie N; Kovanda L; Roy M; Wu C; Arrieta A
Pediatr Infect Dis J; 2013 Nov; 32(11):e419-25. PubMed ID: 23958810
[TBL] [Abstract][Full Text] [Related]
17. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
Cross SA; Scott LJ
Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
Boonstra JM; van der Elst KC; Veringa A; Jongedijk EM; Brüggemann RJ; Koster RA; Kampinga GA; Kosterink JG; van der Werf TS; Zijlstra JG; Touw DJ; Alffenaar JWC
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971861
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients.
Martial LC; Ter Heine R; Schouten JA; Hunfeld NG; van Leeuwen HJ; Verweij PE; de Lange DW; Pickkers P; Brüggemann RJ
Clin Pharmacokinet; 2017 Oct; 56(10):1197-1206. PubMed ID: 28144840
[TBL] [Abstract][Full Text] [Related]
20. Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis.
Wiederhold NP; Najvar LK; Bocanegra R; Kirkpatrick WR; Patterson TF
Clin Microbiol Infect; 2012 Feb; 18(2):E20-3. PubMed ID: 22128831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
